Citigroup Inc Revance Therapeutics, Inc. Call Options Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 09, 2024	BUY	$5.81 - $11.2 $245,762 - $473,759	42,300 Added 22.89%	227,100 $2 Million
Q3 2023 Nov 09, 2023	BUY	$11.47 - $25.07 $285,603 - $624,243	24,900 Added 15.57%	184,800 $2.12 Million
Q2 2023 Aug 10, 2023	SELL	$24.7 - $37.61 $1.72 Million - $2.62 Million	-69,700 Reduced 30.36%	159,900 $4.05 Million
Q1 2023 May 11, 2023	SELL	$18.36 - $35.27 $1.29 Million - $2.48 Million	-70,400 Reduced 23.47%	229,600 $7.4 Million
Q4 2022 Feb 09, 2023	SELL	$18.32 - $30.66 $27.8 Million - $46.5 Million	-1,516,600 Reduced 83.49%	300,000 $5.54 Million
Q3 2022 Nov 10, 2022	BUY	$14.33 - $28.47 $25.1 Million - $49.9 Million	1,751,800 Added 2703.4%	1,816,600 $49 Million
Q2 2022 Aug 10, 2022	BUY	$11.52 - $20.4 $746,496 - $1.32 Million	64,800 New	64,800 $896,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.